200 related articles for article (PubMed ID: 25295576)
21. Reconceptualizing podocyte damage in Fabry disease: new findings identify α-synuclein as a putative therapeutic target.
Germain DP
Kidney Int; 2024 Feb; 105(2):237-239. PubMed ID: 37714429
[No Abstract] [Full Text] [Related]
22. A female heterozygous patient with Fabry's disease with renal accumulation of trihexosylceramide detected with a monoclonal antibody.
Fukushima M; Tsuchiyama Y; Nakato T; Yokoi T; Ikeda H; Yoshida S; Kusumoto T; Itoh K; Sakuraba H
Am J Kidney Dis; 1995 Dec; 26(6):952-5. PubMed ID: 7503071
[TBL] [Abstract][Full Text] [Related]
23. Fabry disease: biochemical, pathological and structural studies of the α-galactosidase A with E66Q amino acid substitution.
Togawa T; Tsukimura T; Kodama T; Tanaka T; Kawashima I; Saito S; Ohno K; Fukushige T; Kanekura T; Satomura A; Kang DH; Lee BH; Yoo HW; Doi K; Noiri E; Sakuraba H
Mol Genet Metab; 2012 Apr; 105(4):615-20. PubMed ID: 22305854
[TBL] [Abstract][Full Text] [Related]
24. A case of Fabry nephropathy with histological features of oligonephropathy.
Nishida M; Kosaka K; Hasegawa K; Nishikawa K; Itoi T; Tsukimura T; Togawa T; Sakuraba H; Hamaoka K
Eur J Pediatr; 2014 Aug; 173(8):1111-4. PubMed ID: 23913314
[TBL] [Abstract][Full Text] [Related]
25. [Pedigree investigation of clinicopathologic features and alpha-galactosidase A gene mutation in a family with Fabry disease].
Liu XX; Yu CW; Yang Y; Hu ZX
Sichuan Da Xue Xue Bao Yi Xue Ban; 2012 Nov; 43(6):948-51. PubMed ID: 23387234
[TBL] [Abstract][Full Text] [Related]
26. Two novel alpha-galactosidase A mutations causing Fabry disease: A missense mutation M11V in a heterozygote woman and a nonsense mutation R190X in a hemizygote man.
Celtikci B; Topçu M; Ozkara HA
Clin Biochem; 2011 Jul; 44(10-11):809-12. PubMed ID: 21569769
[TBL] [Abstract][Full Text] [Related]
27. Fabry heterozygote mimicking multiple sclerosis.
Yau WY; Fabis-Pedrini MJ; Kermode AG
BMJ Case Rep; 2017 Jun; 2017():. PubMed ID: 28576916
[TBL] [Abstract][Full Text] [Related]
28. Screening for Fabry disease in patients undergoing dialysis for chronic renal failure in Turkey: identification of new case with novel mutation.
Okur I; Ezgu F; Biberoglu G; Tumer L; Erten Y; Isitman M; Eminoglu FT; Hasanoglu A
Gene; 2013 Sep; 527(1):42-7. PubMed ID: 23756194
[TBL] [Abstract][Full Text] [Related]
29. Coexistence of Fabry disease with IgM nephropathy: A case report.
Wu H; Behera TR; Gong J; Shen Q
Medicine (Baltimore); 2019 Oct; 98(41):e17566. PubMed ID: 31593141
[TBL] [Abstract][Full Text] [Related]
30. Clinical and genetic analysis of Fabry disease: report of six cases including three heterozygous females.
Nagasaki A; Nishie W; Sato K; Oba I; Noguchi E; Akitsu H; Sawamura D; Shimizu H
J Dermatol Sci; 2008 Oct; 52(1):61-4. PubMed ID: 18555667
[No Abstract] [Full Text] [Related]
31. A novel GLA mutation in a Fabry family with glucose-6-phosphate dehydrogenase deficiency.
Pisani A; Visciano B; Russo R; Mozzillo GR; Porto C; De Maggio I; Russo R; Pontarelli G; Villani GR; Cianciaruso B; Di Natale P
J Nephrol; 2012; 25(4):582-5. PubMed ID: 22307442
[TBL] [Abstract][Full Text] [Related]
32. Beneficial screening of Fabry disease in patients with hypohidrosis.
Nagai-Sangawa M; Fukunaga A; Takeuchi C; Nishiyama S; Horikawa T; Nagano C; Nozu K; Fujii H; Nishigori C
J Dermatol; 2022 Feb; 49(2):308-312. PubMed ID: 34796992
[TBL] [Abstract][Full Text] [Related]
33. A Classical Phenotype of Fabry Disease with Novel Mutation Found by Kidney Biopsy, A Case Report.
Matsumoto K; Ishii M; Mizuta M; Nakamura M; Matsumoto R; Ikeda Y; Yamasaki M; Fukuda M; Miyazono M
Iran J Kidney Dis; 2023 Nov; 17(6):348-350. PubMed ID: 38043112
[TBL] [Abstract][Full Text] [Related]
34. Fabry disease: identification of 50 novel alpha-galactosidase A mutations causing the classic phenotype and three-dimensional structural analysis of 29 missense mutations.
Shabbeer J; Yasuda M; Benson SD; Desnick RJ
Hum Genomics; 2006 Mar; 2(5):297-309. PubMed ID: 16595074
[TBL] [Abstract][Full Text] [Related]
35. Podocyturia in paediatric patients with Fabry disease.
Liern M; Collazo A; Valencia M; Fainboin A; Isse L; Costales-Collaguazo C; Ochoa F; Vallejo G; Zotta E
Nefrologia (Engl Ed); 2019; 39(2):177-183. PubMed ID: 30139698
[TBL] [Abstract][Full Text] [Related]
36. Podocyturia is significantly elevated in untreated vs treated Fabry adult patients.
Trimarchi H; Canzonieri R; Schiel A; Politei J; Stern A; Andrews J; Paulero M; Rengel T; Aráoz A; Forrester M; Lombi F; Pomeranz V; Iriarte R; Young P; Muryan A; Zotta E
J Nephrol; 2016 Dec; 29(6):791-797. PubMed ID: 26842625
[TBL] [Abstract][Full Text] [Related]
37. [Morphological characteristics of renal changes in Fabry disease].
Lerner YV; Tsoy LV; Grishina AN; Varshavsky VA
Arkh Patol; 2022; 84(1):21-26. PubMed ID: 35166474
[TBL] [Abstract][Full Text] [Related]
38. Histologic abnormalities of placental tissues in Fabry disease: a case report and review of the literature.
Thurberg BL; Politei JM
Hum Pathol; 2012 Apr; 43(4):610-4. PubMed ID: 22078290
[TBL] [Abstract][Full Text] [Related]
39. DNA methylation impact on Fabry disease.
Di Risi T; Vinciguerra R; Cuomo M; Della Monica R; Riccio E; Cocozza S; Imbriaco M; Duro G; Pisani A; Chiariotti L
Clin Epigenetics; 2021 Feb; 13(1):24. PubMed ID: 33531072
[TBL] [Abstract][Full Text] [Related]
40. Foot process effacement is an early marker of nephropathy in young classic Fabry patients without albuminuria.
Tøndel C; Kanai T; Larsen KK; Ito S; Politei JM; Warnock DG; Svarstad E
Nephron; 2015; 129(1):16-21. PubMed ID: 25531941
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
